Beijing Kawin Technology Share-Holding Co (688687) Fair Value & Analysis
Healthcare · CN · Market cap 2.8B CNY
Fair value as of: Jun 24, 2026
Analysis
Beijing Kawin Technology Share-Holding Co (688687) currently trades at ¥15.70, while our model-based Fair Value estimate is ¥6.93 — implying the stock looks roughly 55.9% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhizin tablets, capsules, and injections; and pirfenidone tablets for mild to moderate idiopathic pulmonary fibrosis. It is also involved in contract manufacture organization/contract development and manufacturing organization; technology and biotechnology development; technical consulting; biotechnology consulting; science and technology promotion and application; and wholesale of medical supplies. Beijing Kawin Technology Share-Holding Co., Ltd. was incorporated in 2008 and is based in Beijing, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Beijing Kawin Technology Share-Holding Co (688687) undervalued?
What is the fair value of 688687?
What is the quality score of 688687?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.